BMS-955176: Difference between revisions
TonyDewitt (talk | contribs) No edit summary |
m Moving from Category:Experimental drugs to Category:Experimental antiviral drugs using Cat-a-lot |
||
(29 intermediate revisions by 22 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{Multiple issues|{{notability|date=July 2015}}{{technical|date=July 2015}}}} |
|||
{{Infobox drug |
|||
| drug_name = |
|||
| INN = |
|||
| type =<!-- empty --> |
|||
| IUPAC_name = |
|||
| image = BMS-955176.svg |
|||
| alt = |
|||
| caption = |
|||
<!-- Clinical data --> |
|||
| pronounce = |
|||
| tradename = |
|||
| Drugs.com = |
|||
| MedlinePlus = |
|||
| pregnancy_AU = <!-- A/B1/B2/B3/C/D/X --> |
|||
| pregnancy_AU_comment = |
|||
| pregnancy_US = <!-- A/B/C/D/X/N --> |
|||
| pregnancy_category= |
|||
| routes_of_administration = |
|||
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--> |
|||
| legal_AU_comment = |
|||
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> |
|||
| legal_DE = <!-- Anlage I, II, III --> |
|||
| legal_NZ = <!-- Class A, B, C --> |
|||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> |
|||
| legal_US = <!-- OTC/Rx-only/Schedule I, II, III, IV, V --> |
|||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV--> |
|||
| legal_status = Investigational |
|||
<!-- Pharmacokinetic data --> |
|||
| bioavailability = |
|||
| protein_bound = |
|||
| metabolism = |
|||
| metabolites = |
|||
| onset = |
|||
| elimination_half-life = |
|||
| duration_of_action = |
|||
| excretion = |
|||
<!-- Identifiers --> |
|||
| CAS_number = 1392312-45-6 |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 4CA9IAU7RJ |
|||
| ATCvet = |
|||
| ATC_prefix = <!-- 'none' if uncategorised --> |
|||
| ATC_suffix = |
|||
| PubChem = |
|||
| ChemSpiderID = 58922159 |
|||
| DrugBank = |
|||
<!-- Chemical data --> |
|||
| C=42|H=62|N=2|O=4|S=1 |
|||
| molecular_weight = |
|||
| smiles = CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@H]4[C@]([C@@]3(CC2)C)(CC[C@@H]5[C@@]4(CC=C(C5(C)C)c6ccc(cc6)C(=O)O)C)C)NCCN7CCS(=O)(=O)CC7 |
|||
| StdInChI = 1S/C42H62N2O4S/c1-28(2)31-14-19-42(43-22-23-44-24-26-49(47,48)27-25-44)21-20-40(6)33(36(31)42)12-13-35-39(5)17-15-32(29-8-10-30(11-9-29)37(45)46)38(3,4)34(39)16-18-41(35,40)7/h8-11,15,31,33-36,43H,1,12-14,16-27H2,2-7H3,(H,45,46)/t31-,33+,34-,35+,36+,39-,40+,41+,42-/m0/s1 |
|||
| StdInChIKey = XDMUFNNPLXHNKA-ZTESCHFWSA-N |
|||
}} |
|||
'''BMS-955176''' is an experimental [[HIV]] [[maturation inhibitor]] under [[drug development|development]] by [[Bristol-Myers Squibb]] for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.<ref> |
'''BMS-955176''' is an experimental second generation [[HIV]] [[maturation inhibitor]] under [[drug development|development]] by [[Bristol-Myers Squibb]] for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.<ref>{{cite web|url=http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml|title=BMS Maturation Inhibitor Is Potent Against HIV in Early Trial|date=25 February 2015|access-date=22 July 2015|archive-url=https://web.archive.org/web/20150723033900/http://www.aidsmeds.com/articles/BMS_maturation_inhibitor_1667_26859.shtml|archive-date=23 July 2015|url-status=dead}}</ref> First generation maturation inhibitors such as [[bevirimat]] were ineffective against some naturally occurring changes (polymorphisms) in the [[Gag protease]] polyprotein; BMS-955176 has been selected to better tolerate gag [[Polymorphism (biology)|polymorphisms]].<ref>{{cite web|url=http://www.projectinform.org/hiv-news/croi2015-new-hiv-maturation-inhibitor-bms-955176-appears-more-potent-than-earlier-beviramat/|title=CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform}}</ref><ref>{{cite journal | vauthors = Wang D, Lu W, Li F | title = Pharmacological intervention of HIV-1 maturation | journal = Acta Pharmaceutica Sinica B | volume = 5 | issue = 6 | pages = 493–9 | date = November 2015 | pmid = 26713265 | pmc = 4675807 | doi = 10.1016/j.apsb.2015.05.004 }}</ref> |
||
__TOC__ |
|||
== Studies == |
|||
Results of a [[Clinical trial|phase 2a]] trial of BMS-955176 was reported at the 2015 [[Conference on Retroviruses and Opportunistic Infections]] (CROI).<ref name=":0">{{Cite web|title = Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor {{!}} CROI Conference|url = http://www.croiconference.org/sessions/antiviral-activitysafety-second-generation-hiv-1-maturation-inhibitor|website = www.croiconference.org|access-date = 2016-01-01}}</ref> Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.<ref name=":0" /><ref>{{Cite web|title = HIV maturation inhibitor BMS-955176 looks promising in early study|url = http://www.aidsmap.com/HIV-maturation-inhibitor-BMS-955176-looks-promising-in-early-study/page/2948854/|website = www.aidsmap.com|access-date = 2016-01-01}}</ref> |
|||
It appears that development of BMS-955176 has been terminated.<ref>{{cite web|url=http://www.thebodypro.com/content/78689/gsk-discontinues-development-of-maturation-inhibit.html|title=GSK Discontinues Development of Maturation Inhibitor BMS-955176}}</ref> |
|||
⚫ | |||
== See also == |
|||
* [[Fipravirimat]] |
|||
⚫ | |||
{{reflist}} |
{{reflist}} |
||
Line 10: | Line 71: | ||
[[Category:Antiretroviral drugs]] |
[[Category:Antiretroviral drugs]] |
||
[[Category:Maturation inhibitors]] |
[[Category:Maturation inhibitors]] |
||
[[Category:Experimental antiviral drugs]] |
|||
{{antiinfective-drug-stub}} |
Latest revision as of 20:41, 1 December 2023
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C42H62N2O4S |
Molar mass | 691.03 g·mol−1 |
3D model (JSmol) | |
| |
|
BMS-955176 is an experimental second generation HIV maturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] First generation maturation inhibitors such as bevirimat were ineffective against some naturally occurring changes (polymorphisms) in the Gag protease polyprotein; BMS-955176 has been selected to better tolerate gag polymorphisms.[2][3]
Studies
[edit]Results of a phase 2a trial of BMS-955176 was reported at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI).[4] Investigators concluded that the drug was well tolerated and effective against HIV, including strains with gag polymorphisms.[4][5]
It appears that development of BMS-955176 has been terminated.[6]
See also
[edit]References
[edit]- ^ "BMS Maturation Inhibitor Is Potent Against HIV in Early Trial". 25 February 2015. Archived from the original on 23 July 2015. Retrieved 22 July 2015.
- ^ "CROI2015: New HIV maturation inhibitor BMS-955176 appears more potent than earlier beviramat - Project Inform".
- ^ Wang D, Lu W, Li F (November 2015). "Pharmacological intervention of HIV-1 maturation". Acta Pharmaceutica Sinica B. 5 (6): 493–9. doi:10.1016/j.apsb.2015.05.004. PMC 4675807. PMID 26713265.
- ^ a b "Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor | CROI Conference". www.croiconference.org. Retrieved 2016-01-01.
- ^ "HIV maturation inhibitor BMS-955176 looks promising in early study". www.aidsmap.com. Retrieved 2016-01-01.
- ^ "GSK Discontinues Development of Maturation Inhibitor BMS-955176".